Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib in Japanese subjects with advanced solid tumors
NCT02210663Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib in solid tumor (advanced stage), sponsored by AbbVie Inc. Primary endpoint: Dose-limiting toxicities at 28 days. Started Jul 2014; status: completed.
02
Drugs
veliparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02210663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210663.